Mega Contracts Monitor ($100M+) — July 24, 2026

Leidos Holdings subsidiary won a $173.3 million cost-plus-fixed-fee delivery order from the NIH National Cancer Institute for Phase 1/2 vaccine trials through 2029, with $36.8 million already funded. The cost-plus structure minimizes profit volatility and provides ~$29 million annual revenue.

Frequentis USA secured a $124.6 million delivery order for APC units and APCMS under time-and-materials pricing, with $105.1 million already outlayed. The high funding certainty and essential air traffic operations support stable near-term revenue of ~$50 million annually through 2027.

Raytheon (RTX) received a $113.2 million sole-source, cost-plus-fixed-fee delivery order under the FAA's STARS program for ground handling equipment engineering. While the non-competed nature confirms incumbency, the $28 million annual revenue is immaterial for RTX ($69B+ revenue) and cost-plus caps margin upside.

PTSI Managed Services' $130.8 million NASA Goddard facility contract is 78% paid and expired in September 2023. No follow-on awards are visible in this monitor, suggesting potential revenue gap for PTSI and possible loss of NASA infrastructure work to competitors.

Frequentis USA is foreign-owned (Austrian parent) but U.S.-incorporated, winning a $124.6 million FAA telecom contract. Regulatory changes targeting foreign-owned defense/transportation contractors could disrupt future awards or impose compliance costs.

All four contracts are civilian (HHS, NASA, FAA), making them vulnerable to discretionary budget cuts or continuing resolution delays. The $541.8 million total is 100% civilian, with no defense funding buffer.

Leidos' $173.3 million NIH vaccine trial contract positions the company for expanded health R&D work. Successful Phase 1/2 outcomes could lead to larger Phase 3 contracts or follow-on awards from other NIH institutes.

Raytheon's sole-source $113.2 million FAA STARS award demonstrates incumbency advantage. Future STARS program modifications or expansions could yield additional non-competed task orders for RTX.

With zero defense contracts in this monitor, defense-exposed investors may rotate into civilian-heavy names like Leidos or RTX for budget diversification. Leidos' health R&D work is particularly resilient to defense budget volatility.

Two of four contracts ($237.7 million combined) are for FAA air traffic control equipment and NASA facility construction, signaling sustained investment in civilian transportation and space infrastructure. Frequentis USA's $124.6 million telecom award and PTSI's $130.8 million facility contract both support modernization of aging federal assets.

Leidos' $173.3 million NIH vaccine trial contract exemplifies the stability of health R&D contracting. Cost-plus pricing and long performance periods (6 years) offer predictable margins, contrasting with fixed-price defense work.

{"entity" => "PTSI Managed Services Inc.", "reason" => "Its $130.8 million NASA Goddard contract is 78% paid and expired in 2023, with no visible follow-on. Revenue gap risk is high.", "trigger" => "NASA GSFC facility contract re-compete announcement or modification"}

{"entity" => "Frequentis USA Inc.", "reason" => "Foreign ownership on a $124.6 million FAA telecom contract creates regulatory risk; contract runs through 2027.", "trigger" => "CFIUS review, FAA foreign ownership policy change, or NDAA provision"}

{"entity" => "Leidos Holdings Inc.", "reason" => "Only $36.8 million of $173.3 million NIH contract is funded; full realization depends on future obligations.", "trigger" => "NIH budget allocation for cancer vaccine trials, option exercise announcements"}